- Home
- NAT vs SVRA Comparison
NAT vs SVRA Comparison
Compare NAT & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAT
- SVRA
- Stock Information
- Founded
- NAT 1995
- SVRA N/A
- Country
- NAT Bermuda
- SVRA United States
- Employees
- NAT N/A
- SVRA N/A
- Industry
- NAT Marine Transportation
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- NAT Consumer Discretionary
- SVRA Health Care
- Exchange
- NAT Nasdaq
- SVRA Nasdaq
- Market Cap
- NAT 517.8M
- SVRA 458.2M
- IPO Year
- NAT 1997
- SVRA N/A
- Fundamental
- Price
- NAT $2.81
- SVRA $2.85
- Analyst Decision
- NAT Hold
- SVRA Buy
- Analyst Count
- NAT 2
- SVRA 7
- Target Price
- NAT $3.75
- SVRA $9.86
- AVG Volume (30 Days)
- NAT 3.0M
- SVRA 1.0M
- Earning Date
- NAT 02-27-2025
- SVRA 03-06-2025
- Dividend Yield
- NAT 14.21%
- SVRA N/A
- EPS Growth
- NAT N/A
- SVRA N/A
- EPS
- NAT 0.30
- SVRA N/A
- Revenue
- NAT $367,467,000.00
- SVRA N/A
- Revenue This Year
- NAT N/A
- SVRA N/A
- Revenue Next Year
- NAT $17.77
- SVRA N/A
- P/E Ratio
- NAT $9.09
- SVRA N/A
- Revenue Growth
- NAT N/A
- SVRA N/A
- 52 Week Low
- NAT $2.41
- SVRA $2.59
- 52 Week High
- NAT $4.40
- SVRA $5.70
- Technical
- Relative Strength Index (RSI)
- NAT 56.57
- SVRA 47.32
- Support Level
- NAT $2.66
- SVRA $2.62
- Resistance Level
- NAT $2.85
- SVRA $2.91
- Average True Range (ATR)
- NAT 0.10
- SVRA 0.18
- MACD
- NAT 0.01
- SVRA 0.02
- Stochastic Oscillator
- NAT 64.29
- SVRA 47.71
About NAT Nordic American Tankers Limited
Nordic American Tankers Ltd owns and operates double hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters pursuant to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.